River Styx Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2017
NCT02950467
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

RiverStyx Foundation

Active Ingredients

Drugs in Phase 2 Trials (1)

psilocybin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1